ライフサイエンスコーパス: PDGF

1 PDGF receptor alpha mRNA correlated with CCN2 and other

2 PDGF receptor beta (PDGFRbeta) is highly expressed in ac

3 PDGF receptor beta-positive myofibroblasts isolated from

4 PDGF, but not VEGF, peptides caused mechanical hypersens

5 PDGF-alpha-syn transgenic (tg) male and female mice were

6 PDGF-BB levels decreased significantly in samples collec

7 PDGF-BB maintained ERK activation in the presence of rux

8 PDGF-DD engagement of NKp44 triggered NK cell secretion

9 PDGF/VEGF ligands regulate a plethora of biological proc

10 tion include c-MYC, KRAS, c-KIT, HIF-1alpha, PDGF-A and hTERT.

11 ansiently increases with elevation of Ang-2, PDGF-BB, and blood glucose; is rapidly reversed on a tim

12 Nintedanib targets VEGF receptors 1-3, PDGF receptors alpha and beta, FGF receptors 1-3, and Sr

13 h factor]), and cluster 4 (n=37; IL-8, IL-4, PDGF-beta [platelet-derived growth factor beta], IL-6, C

14 rovide the first evidence in a metazoan of a PDGF/VEGF ligand acting as a myokine that regulates syst

15 igration (IC(5)(0) congruent with 1 nM) to a PDGF gradient and reduced TNF-alpha-stimulated p65 trans

16 Using a PDGF-B-driven proneural glioma mouse model, we assessed

17 its ligand platelet-derived growth factor A (PDGF-A) are co-expressed in migrating cranial NC.

18 MCP-1, MIP-1alpha, IL-12p70, IL-18, VEGF-A, PDGF-BB and IL-1RA significantly correlated with disease

19 Ectopic platelet-derived growth factor-AA (PDGF-AA) protein induces new tenocyte production while i

20 ed upon JAK2 inhibition in vivo, and PDGF-AA/PDGF-BB production persisted in the setting of JAK inhib

21 adient of platelet-derived growth factor-AB (PDGF-AB) expedites migration through native tissue.

22 or [EGF], platelet-derived growth factor AB [PDGF-AB], and albumin) were measured in fresh and lyophi

23 ion of genes associated with Wnt activation, PDGF- and integrin-binding.

24 Active PDGF-AA/alphaalpha signaling results in phosphorylation

25 b mesylate and a monoclonal antibody against PDGF receptor-alpha enhanced myocardial damage evidenced

26 In mouse cardiac allografts PDGF receptor-beta, but not -alpha intragraft messenger

27 ed diminished expression of integrin alpha1, PDGF-R1beta and connexin-43.

28 stimulated with IL (interleukin)-1alpha and PDGF (platelet-derived growth factor)-BB with SMILR knoc

29 actors, including IGF-1, FGF2, IL-1beta, and PDGF-A, was altered in TLR4-deficient injured spinal cor

30 hers showed that P130CAS mediates VEGF-A and PDGF signalling in vitro, but its cardiovascular functio

31 UB cells synthesize VEGF-A and PDGF-BB proteins and RNA, whereas the MM cells express t

32 n wounds in diabetic mice with VEGF-A165 and PDGF-BB incorporated within VWF A1 HBD-functionalized fi

33 similar observations with EGF, PDGF-AA, and PDGF-BB.

34 TFF3, Serpin E-1, VCAM-1, Vitamin D BP, and PDGF-AA, were significantly upregulated in cancer surviv

35 t, the controlled release of collagenase and PDGF-AB increases cellularity at the interface and withi

36 inflammatory genes, such as CXCL1, CXCL6 and PDGF-A in plaque.

37 mbrane proteins, and members of ERK, FGF and PDGF signaling pathways, which play key roles in glandul

38 GF and PDGF, we embed VEGF in fibrin gel and PDGF in a heparin-based coacervate that is distributed i

39 ponse to C. trachomatis infection, IL23A and PDGF were significantly upregulated in scarring progress

40 h mesangial cell markers alpha8-integrin and PDGF receptor-beta but not with endothelial, podocyte, o

41 tic interaction between FGF-induced MAPK and PDGF-induced PI3K signaling.

42 F2, IGFBP-3 binds bFGF, HGF, neuregulin, and PDGF AB with nanomolar affinity.

43 B:R2 KD = 110 pM, PDGF-BB:R2 KD = 40 nM, and PDGF-CC:R2 KD = 70 pM.

44 f pro-regenerative factors including OSM and PDGF-AA.

45 ly observed increases in PTP1B oxidation and PDGF receptor phosphorylation in TrxR1 knockout cells.

46 e collagenase (to increase ECM porosity) and PDGF-AB (to attract endogenous cells) in a localized and

47 inase inhibitor which inhibits both VEGF and PDGF receptors.

48 To achieve sequential release of VEGF and PDGF, we embed VEGF in fibrin gel and PDGF in a heparin-

49 7 following surgery, mean levels of VEGF and PDGF-BB at sites treated with PRGF and PRF were not sign

50 30 after therapy for evaluation of VEGF and PDGF-BB levels.

51 nhanced autocrine signaling through VEGF and PDGF.

52 including the proangiogenic factors VEGF and PDGF.

53 activated upon JAK2 inhibition in vivo, and PDGF-AA/PDGF-BB production persisted in the setting of J

54 beta antibody, iii) by administering an anti-PDGF-AB/BB aptamer, and iv) by using small chemical inhi

55 hances PDGF-driven gliomas in vivo, augments PDGF-induced Akt and STAT3 signaling in vitro, while nex

56 Because platelet-derived growth factor B (PDGF-B) signaling has a pivotal role in mesangial cell p

57 that platelet-derived growth factor (PDGF)-B/PDGF receptor beta (PDGFRbeta) signalling is critical in

58 oped label-free electrochemical C-MEMS based PDGF-BB aptasensor is highly sensitive, selective, and r

59 with both platelet-derived growth factor-BB (PDGF-BB) and vascular endothelial growth factor (VEGF-16

60 levels of platelet derived growth factor-BB (PDGF-BB) in gingival crevicular fluid (GCF) during early

61 GF-A) and platelet-derived growth factor-BB (PDGF-BB) that were engineered to have a syndecan-binding

62 lpha) and platelet-derived growth factor-BB (PDGF-BB) were reduced.

63 forms and platelet-derived growth factor-BB (PDGF-BB), mainly through the heparin-binding domain (HBD

64 agonist, platelet-derived growth factor-BB (PDGF-BB)-induced p21Cip1 degradation and HASMC prolifera

65 PGZ on i) platelet-derived growth factor-BB (PDGF-BB)-stimulated proliferation of human venous smooth

66 ection of platelet-derived growth factor-BB (PDGF-BB).

67 GF-A) and platelet-derived growth factor-BB (PDGF-BB).

68 ressing platelet-derived growth factor beta (PDGF-B), constitutive HRAS, and shRNA-p53 respectively.

69 a], and platelet-derived growth factor-beta [PDGF-beta]) and blood-brain barrier (BBB) occludin and z

70 difference in capillary rarefaction between PDGF-CC-neutralized mice and mice with intact PDGF-CC.

71 In vitro, blocking PDGF signaling decreased elastogenic gene expression ass

72 c deletion of host IL-33 in mice also blocks PDGF-BB-induced TAM recruitment and metastasis.

73 ts appropriate ligand-mediated activation by PDGF-AA.

74 iferation and its expression is decreased by PDGF-B.

75 without a concurrent increase in fibrosis by PDGF application.

76 nt malignant cell heterogeneity modulated by PDGF-DD signaling in pancreatic neuroendocrine tumors (P

77 h was delayed in the absence of signaling by PDGF-DD.

78 y reduces fibroblast migration stimulated by PDGF-BB and reduced in vivo lung fibrosis in mice.

79 HSV carrying PDGF siRNA was established and intrathecally injected in

80 and platelet-derived growth factor B chain (PDGF-BB), to stimulate MM cell differentiation.

81 Sunitinib also inhibited chronic PDGF-A and -B and VEGF-A and -B expressions.

82 Conversely, continuous PDGF-B infusion in healthy rats induced DbpA expression

83 inflammatory response, such as CXCL1, CXCL6, PDGF-A, MCP-1 and IL-6.

84 organ-specific metabolic roles of Drosophila PDGF/VEGF-like factors (Pvfs).

85 We made similar observations with EGF, PDGF-AA, and PDGF-BB.

86 GFR activation loop that involved endogenous PDGF.

87 TrkB.T1 enhances PDGF-driven gliomas in vivo, augments PDGF-induced Akt a

88 e biopsy samples from DMD patients expressed PDGF-BB.

89 olled the dissemination of tumors expressing PDGF-DD more effectively than control mice, an effect en

90 Finally, the growth factor PDGF induced CAP1 dephosphorylation, suggesting CAP1 may

91 Platelet-derived growth factor (PDGF) acts through two conserved receptor tyrosine kinas

92 tors such as platelet-derived growth factor (PDGF) and the activation of the ERK1/2 are major regulat

93 sion of both platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) is i

94 ride-induced platelet-derived growth factor (PDGF) and Wnt signaling pathways.

95 York, NY), a platelet-derived growth factor (PDGF) antagonist, administered in combination with the a

96 The Platelet Derived Growth Factor (PDGF) family of ligands have well established functions

97 TNF-alpha or platelet-derived growth factor (PDGF) followed by evaluation of ECM production and depos

98 tative being platelet-derived growth factor (PDGF) isoforms (PDGF-AA, -BB, and -AB), insulin-like gro

99 l model of a platelet-derived growth factor (PDGF) protein and its DNA aptamer, which was selected in

100 The platelet-derived growth factor (PDGF) receptor (PDGFR) family of receptor tyrosine kinas

101 While platelet-derived growth factor (PDGF) receptor alpha (PDGFRalpha) has well-documented fu

102 r (VEGF) and platelet-derived growth factor (PDGF) receptors, has single-agent activity in non-small-

103 gradient of platelet-derived growth factor (PDGF) requires signaling through the phospholipase C (PL

104 to enhanced platelet-derived growth factor (PDGF) signaling are commonly observed in the proneural s

105 receptor for platelet-derived growth factor (PDGF) signaling recruits the p85 subunit of Phosphoinosi

106 how that the platelet-derived growth factor (PDGF) signalling pathway is activated in mutant iPSC-CMs

107 insulin and platelet-derived growth factor (PDGF) using the Aptamer-SWNT hybrids and the Aptamer-Anc

108 A) targeting platelet-derived growth factor (PDGF) was used to alleviate bone cancer pain.

109 Platelet-derived growth factor (PDGF), a potent mitogen for cells of mesenchymal origin,

110 gradient of platelet-derived growth factor (PDGF), together with other spatial cues.

111 a (TGFbeta), platelet-derived growth factor (PDGF), WNT and hedgehog signalling drive disease progres

112 In vitro platelet-derived growth factor (PDGF)- and tumor necrosis factor-alpha (TNF-alpha)-induc

113 , including platelet- derived growth factor (PDGF)-AA/alphaalpha, are linked to primary cilia.

114 we show that platelet-derived growth factor (PDGF)-B/PDGF receptor beta (PDGFRbeta) signalling is cri

115 Platelet-derived growth factor (PDGF)-BB belongs to a family of growth factors that regu

116 rand factor, platelet-derived growth factor (PDGF)-BB, angiopoietin-1, and lysyl oxidase-2 and the ce

117 treated with platelet-derived growth factor (PDGF)-BB.

118 ta 2 (FOG2), platelet-derived growth factor (PDGF)-beta, and phosphatidic acid phosphatase 2b (PPAP2B

119 r PDGFRbeta, platelet-derived growth factor (PDGF)-DD, opened the possibility of a previously unident

120 mors produce platelet-derived growth factor (PDGF)-DD, which promotes cellular proliferation, epithel

121 ivation in a platelet-derived growth factor (PDGF)-dependent manner.

122 nt two novel platelet-derived growth factor (PDGF)-driven mouse models of pediatric supratentorial HG

123 27 inhibited platelet-derived growth factor (PDGF)-induced migration in human VSMCs.

124 es and mice, platelet-derived growth factor (PDGF)-like signaling induced mesencephalic astrocyte-der

125 ombined VEGF/platelet-derived growth factor (PDGF)/FGF receptor inhibitors, paracrine ERK activation

126 VEGF) and 2) platelet-derived growth factor (PDGF-BB) in gingival crevicular fluid (GCF) from localiz

127 that the presence of fibrotic growth factor, PDGF-AA, results in increased proliferation of PDGFRalph

128 Platelet-derived growth factors (PDGF) have an ambiguous role in this deleterious cascade

129 Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) make profound contri

130 We computationally predict that cross-family PDGF binding could contribute up to 96% of VEGFR2 ligati

131 erated from exogenous stimulation with FGF2, PDGF, and hGF and readily prevented MBC cell growth indu

132 ficant difference in proliferation following PDGF exposure.

133 PI3K recruitment of ZC3H14 is necessary for PDGF-induced neuroprotection and that this interaction i

134 hese results show that CRMP2 is required for PDGF-directed cell migration in vitro.

135 ion in rats, suggesting a conserved role for PDGF and VEGFR-2 signaling in regulating mechanical noci

136 ion, consistent with an instructive role for PDGF signaling.

137 A role for PDGF-BB in vasculogenesis in the 3D MM/UB co-culture sys

138 ion strategies provided high selectivity for PDGF-BB and high stability of 90.34% after 10 days.

139 f TGF-beta upregulated invadosome formation, PDGF-B mRNA expression, and phosphorylation of PDGFR.

140 tly bound to and activated Usp1 Furthermore, PDGF-mediated expression of USP1 led to the stabilizatio

141 Moreover, we generate PDGF-BB- and VEGFA-hypersecreting hMSC lines as short-te

142 On one hand, PDGF may exert vascular stabilizing and antiapoptotic ac

143 osstalk in the heart; and on the other hand, PDGF signaling mediates neointimal formation and exacerb

144 r, we demonstrate activity for heterodimeric PDGF-AB ligand in the vigorous activation of PDGFR-beta

145 However, PDGF-B/PDGFRbeta signalling is expendable for maintainin

146 However, PDGF-BB stimulated MM cell proliferation, migration, and

147 membrane (CM) treated with recombinant human PDGF-BB (rhPDGF-BB).

148 -mediated gene transfer of recombinant human PDGF-BB upregulated messenger RNA expression of anti-mes

149 tional mouse mutagenesis, we here identified PDGF-PDGFRbeta signaling as critical functional mediator

150 We identified PDGF-D as a CMV-induced factor essential for pericyte re

151 In mice challenged with angiotensin II, PDGF receptor alpha-positive cells were increased in the

152 receptor-beta cell interactions to implicate PDGF-BB as a primary effector of MM cell vasculogenesis.

153 sphatase inhibitor okadaic acid, implicating PDGF-induced activation of protein phosphatase 1 (PP1) i

154 In NSCLC alterations in PDGF receptors are markers of worst prognosis and effici

155 c small interfering RNA induced apoptosis in PDGF-activated fibroblasts, but not in quiescent fibrobl

156 roliferation and migration and is crucial in PDGF-BB pathway in VSMCs.

157 a large (Bcl-xL) as a key survival factor in PDGF-activated human and mouse fibroblasts.

158 h activation of SOX7 transcription factor in PDGF-BB-stimulated pericytes.

159 old in HGF, 2.9-fold in VEGF and 8.7-fold in PDGF-B higher gene expressions compared to BMSCs.

160 xpanding the range of proteins implicated in PDGF signalling pathways.

161 loss of expression of oncogenes involved in PDGF, EGFR, VEGF, insulin/IGF/MAPKK, FGF, Hedgehog, TGFb

162 cytes, PI3Kalpha was selectively involved in PDGF-B expression, whereas both PI3Kalpha and PI3Kdelta

163 We found that Prx2 becomes oxidized in PDGF-treated fibroblasts, but only when TrxR1 has first

164 This includes PDGF secretion from alveolar type I and type II cells, c

165 Heparin, which binds ligands including PDGF and SCF, and imatininib which blocks downstream tyr

166 gut development and regeneration, including PDGF-A, IGFBP-3, IGFBP-2, and IGF-1.

167 However, both increased PDGF ligand abundance and enhanced PDGFRalpha pathway ac

168 r proneural glioblastoma featuring increased PDGF signaling.

169 ing regeneration, acts as a decoy to inhibit PDGF signalling and to prevent FAP over-activation.

170 RK1/2 inhibitors are effective at inhibiting PDGF-mediated proliferation, collagen production, and IL

171 Thus, miR-125a-5p in this context inhibits PDGF-BB pathway and is therefore a potential regulator o

172 Our results indicate that NOTCH2 inhibits PDGF-B-dependent proliferation and its expression is dec

173 Subsequent experiments revealed that intact PDGF-B signaling, mediated via Olfml3 binding, is requir

174 DGF-CC-neutralized mice and mice with intact PDGF-CC.

175 telet-derived growth factor (PDGF) isoforms (PDGF-AA, -BB, and -AB), insulin-like growth factor bindi

176 rowth factor], sCD40L [soluble CD40 ligand], PDGF [platelet-derived growth factor], RANTES [regulated

177 By selective activation of PI3K and MAPK, PDGF and FGF cooperate with and oppose each other to bal

178 ce plasmon resonance to identify and measure PDGF-to-VEGFR binding rates, establishing cut-offs for b

179 We discovered new PDGF:VEGFR2 interactions with PDGF-AA:R2 KD = 530 nM, PD

180 R2 interactions with PDGF-AA:R2 KD = 530 nM, PDGF-AB:R2 KD = 110 pM, PDGF-BB:R2 KD = 40 nM, and PDGF-

181 Surprisingly, ablation of PDGF-DD did not affect the vasculature or stroma of PanN

182 reased Akt phosphorylation in the absence of PDGF-AA stimulation, which we show is due to impaired de

183 proteomics study, using a SILAC approach, of PDGF-stimulated mouse embryonic fibroblasts (MEFs).

184 The rules governing the binding of PDGF ligand to the receptor to produce activation and do

185 strocytic growth by intravitreal delivery of PDGF-A was sufficient to block retinal vascular pruning

186 ferentiation and implicate downregulation of PDGF signaling as a critical event in the transition fro

187 RhoG is activated by Trio downstream of PDGF in a PI3K- and Src-dependent manner.

188 s describe a signaling cascade downstream of PDGF that sustains proneural glioblastoma cells and sugg

189 d VCAM-1 appear to be involved downstream of PDGF-PDGFRbeta.

190 gial cells confirmed a stimulatory effect of PDGF-B on DbpA transcript numbers and protein levels.

191 ration, we examined the regulatory effect of PDGF-B on DbpA.

192 Independent of the effect of PDGF-CC neutralization on renal fibrosis, we found no di

193 e is known about the downstream effectors of PDGF signaling in glioblastoma.

194 tro experiments to understand the effects of PDGF-BB on myoblasts involved in the pathophysiology of

195 d on days 3, 7, 14, and 30 for evaluation of PDGF-BB levels and alkaline phosphatase (ALP) levels.

196 d TRIM27 knockdown reduced the expression of PDGF receptor-beta (PDGFRbeta) and the phosphorylation o

197 The expression of PDGF-AA and BMP2 was positively regulated by the p38 MAP

198 cells, likely due to decreased expression of PDGF-AA and BMP2.

199 We analyzed the expression of PDGF-BB in muscle biopsy samples from controls and patie

200 However, the precise function of PDGF-DD in tumor growth and invasion remains elusive.

201 roblasts responding to a shallow gradient of PDGF, signifying polarization.

202 Depletion of CRMP2 resulted in impairment of PDGF-mediated cell migration in an in vitro wound healin

203 Our data indicate that inhibition of PDGF signaling presents an attractive therapeutic approa

204 Inhibition of PDGF-A/PDGFRalpha blocks NC migration by inhibiting N-ca

205 tic potential of crenolanib, an inhibitor of PDGF receptor signaling, in cultured fibroblasts and in

206 Intrathecal injection of PDGF siRNA and morphine reversed thermal and mechanical

207 odel of DMD with repeated i.m. injections of PDGF-BB.

208 PDE levels of PDGF-AA, platelet glycoprotein VI, integrin-linked kinas

209 Levels of PDGF-BB and VEGF were higher in the PRGF-treated group,

210 ys 3 and 7 following surgery, mean levels of PDGF-BB at sites treated with PRF membrane or CM incorpo

211 th rhPDGF-BB showed comparable GCF levels of PDGF-BB initially with PRF showing more sustained levels

212 d [Ca(2+) ] levels, affecting mRNA levels of PDGF-BB, RICTOR, and MIR17HG as mediators of Ca(2+) -sig

213 ory elements in the widely accepted model of PDGF activity.

214 synoviocytes that involves the production of PDGF-B induced by TGF-beta.

215 Here we show that endothelial production of PDGF-CC during white adipose tissue (WAT) angiogenesis r

216 Thus, while cancer cell production of PDGF-DD supports tumor growth and stromal reaction, it c

217 b axis in osteoclasts, with the promoters of PDGF-AA and BMP2 having Creb binding sites.

218 DGFB) plays a crucial role in recruitment of PDGF receptor beta-positive pericytes to blood vessels.

219 In addition, helix-structural refolding of PDGF binding aptamers (PBA) indirectly wrapped on the SW

220 The role of PDGF-BB in muscle regeneration in humans has not been st

221 A distinctive transcriptional signature of PDGF-DD-induced cytokines and the downregulation of tumo

222 ults indicate that DbpA is a novel target of PDGF-B signaling and a key mediator of mesangial cell pr

223 are key to a more complete understanding of PDGF ligand-receptor interactions and their downstream s

224 nderlying collagen and migrated dependent on PDGF or serum.

225 ing imaginal disc by activating the oncogene PDGF/VEGF-receptor (Pvr).

226 Among the PDGF-A-D isoforms, only PDGF-B was found both significantly elevated in FLS line

227 Interference with PDGFR activation or PDGF neutralization inhibited invadosome formation in RA

228 TNF-alpha or PDGF significantly (P < 0.001) increased ECM deposition

229 Furthermore, TNF-alpha- or PDGF-induced ECM gene expression in ASM cells was signif

230 dated by direct interference with PDGF-BB or PDGF receptor-beta cell interactions to implicate PDGF-B

231 aracteristics when exposed to cholesterol or PDGF (platelet-derived growth factor).

232 bone morphogenetic protein 4 (BMP4), EGF, or PDGF was unaffected by the TAT-SNX9 peptide.

233 EB), and cAMP response element (CRE)-Luc, or PDGF-induced cyclin D1 expression.

234 F-AA:R2 KD = 530 nM, PDGF-AB:R2 KD = 110 pM, PDGF-BB:R2 KD = 40 nM, and PDGF-CC:R2 KD = 70 pM.

235 cells revealed that melanoma cells produced PDGF-BB and TGFbeta, which blocked PEDF production in fi

236 Our results lead us to propose PDGF-A/PDGFRalpha signalling as a tissue-autonomous regu

237 in MCMV+ mice, inhibiting MCMV reactivation, PDGF-D expression, pericyte recruitment, and tumor angio

238 binding, e.g., VEGFs bind to VEGF receptors, PDGFs bind to PDGF receptors, etc.

239 cells and innate lymphoid cells, recognizes PDGF-DD.

240 which was recently identified as a requisite PDGF-gradient-sensing pathway, with the goal of identify

241 Based on our results, PDGF-BB may play a protective role in muscular dystrophi

242 to provide early instructive cue and retain PDGF-B along newly formed vessels to achieve optimal ang

243 We demonstrated that the RTK PDGF/VEGF receptor (Pvr) and its ligands (Pvfs 2 and 3)

244 t once NC cells have undergone EMT, the same PDGF-A/PDGFRalpha works as an NC chemoattractant, guidin

245 only weakly amplifies signaling in a shallow PDGF gradient, but it synergizes with other feedback mec

246 ncluding toll-like receptor (TLR) signaling, PDGF- and angiotensin-regulated airway remodeling, the J

247 These results demonstrate that PDGF siRNA can effectively treat pain induced by bone ca

248 parative transcriptomics, we determined that PDGF signaling upregulated ubiquitin-specific peptidase

249 Mechanistically, we found that PDGF signaling regulated the expression of the E2F trans

250 In this study, we found that PDGF-BB-induced synthetic SMCs suppressed EC proliferati

251 or stroma of PanNET; instead, we found that PDGF-DD stimulated bulk tumor cell proliferation by indu

252 We further show that PDGF-CC stimulation upregulates UCP1 expression and acqu

253 ious contexts of infection, and suggest that PDGF BB and NEDD9 play important roles in this interacti

254 Our results suggest that PDGF-B signaling may play a role in endothelial and card

255 in zebrafish pdgfra mutants, suggesting that PDGF signaling steers cardiomyocytes toward the midline

256 The PDGF receptor tyrosine kinase inhibitor imatinib mesylat

257 Among the PDGF-A-D isoforms, only PDGF-B was found both significan

258 e (PD) that expresses GFP-ASYN driven by the PDGF-beta promoter, we investigated how accumulation of

259 us uncover a novel mode of signaling for the PDGF family during vertebrate development.

260 ngitudinal live imaging of the retina in the PDGF-alpha-syn::GFP mice might represent a useful, non-i

261 xpression levels or decreased binding of the PDGF ligand to PDGFRbeta.

262 findings suggest that the activation of the PDGF pathway contributes to the pathogenesis of LMNA-rel

263 rmacological and molecular inhibition of the PDGF signalling pathway ameliorated the arrhythmic pheno

264 oma cells and suggest that inhibition of the PDGF-E2F-USP1-ID2 axis could serve as a therapeutic stra

265 gfr/MEK-induced tumor growth and produce the PDGF- and VEGF-related factor 1 (Pvf1) ligand to non-aut

266 onstrate that, after ligand stimulation, the PDGF beta receptor (PDGFRbeta) becomes ubiquitinated in

267 anNET characterized by signaling through the PDGF-DD/PDGFRbeta axis.

268 These PDGF receptor alpha-positive cells co-localized with PDG

269 several proteins, including human thrombin, PDGF-BB, Avidin, and His-tagged recombinant protein, wer

270 VEGFs bind to VEGF receptors, PDGFs bind to PDGF receptors, etc.

271 athogenesis of LMNA-related DCM and point to PDGF receptor-beta (PDGFRB) as a potential therapeutic t

272 The results suggest that, in response to PDGF stimulation, PDGFR activity is evenly distributed a

273 gulated and 45 down-regulated in response to PDGF stimulation.

274 showed decreased P-Akt(S473) in response to PDGF-AA upon anterograde transport disruption.

275 s well as with the PDGFRbeta, in response to PDGF-BB stimulation.

276 enuates PDGFRalpha activation in response to PDGF-BB, and reduced phosphorylation of extracellular si

277 PI3K/AKT signaling and dampened response to PDGF-induced mitochondrial fission and reactive oxygen s

278 ollagen deposition, partially in response to PDGFs.

279 and Cbl-b were more prone to migrate toward PDGF-BB, whereas no reproducible effect on cell prolifer

280 s (PHH3(+) mitotic cells, YAP translocation, PDGF secretion) or increase collagen presence.

281 ion and CAF-induced tumor cell invasion upon PDGF-BB stimulation.

282 ative response of Olfml3(-/-) pericytes upon PDGF-B stimulation was significantly diminished.

283 increase in P-Akt(S473) or P-Akt(T308) upon PDGF-AA stimulation.

284 vation, and that combined inhibition of VEGF/PDGF/FGF receptors is sufficient to inhibit mitogenic si

285 In vitro, PDGF-BB attracted myoblasts and activated their prolifer

286 FOG2 regulates VEGF expression, whereas PDGF-beta and PPAP2B regulate Akt activity.

287 The mechanism by which PDGF regulates pain was also investigated by comparing t

288 ll as reduced tumour growth (associated with PDGF-BB delivery) and vascular permeability (triggered b

289 discovered new PDGF:VEGFR2 interactions with PDGF-AA:R2 KD = 530 nM, PDGF-AB:R2 KD = 110 pM, PDGF-BB:

290 To interfere with PDGF-B signaling, we injected nephritic rats with PDGF-B

291 em was validated by direct interference with PDGF-BB or PDGF receptor-beta cell interactions to impli

292 eptor alpha-positive cells co-localized with PDGF receptor beta, procollagen, and periostin.

293 Consistently, in VSMCs pretreated with PDGF-BB, calpastatin induction and calpains inhibition s

294 B signaling, we injected nephritic rats with PDGF-B neutralizing aptamers or the MEK/ERK inhibitor U0

295 In response to stimulation with PDGF, CRMP2 was dephosphorylated on Thr514, an event kno

296 In wild-type cells treated with PDGF-AA, c-Cbl becomes enriched in the cilium, and the r

297 -to-mesenchymal transition when treated with PDGF-BB and TGFbeta1, resulting in vascular SMCs that di

298 sis of muscles from the animals treated with PDGF-BB showed an increased population of satellite cell

299 period of serum deprivation, treatment with PDGF leads to the rapid formation of dramatic, actin-ric

300 pillary rarefaction in mice with and without PDGF-CC neutralization (using genetically deficient mice